You actually taunted him and others above as you have done a hundred times on these threads. You are this time as disingenuous as your earlier and past insults and attempts at discussing IPSC's, unintelligent.
Yawn, once again, be a good lad and go and look at the ever growing list of IPSC applications under trials approved for investigation under NDA's by the FDA since Cynata in May 2022. Heart failure; Retina disorders; Parkinsons Disease; etc. They've been discussed on these threads, that you insist on commenting on, in uninformed fashion. Yawn, once more. Go read up on how Induced pluripotent stem cells were first generated by Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University, Japan, way back in 2006!
Did you pluck 10 years from you know where, or perhaps count your toes? And I loaded up on MSB at $0.26 in the capital raise? What the hell has that, or you being apparently allowed to buy MSB at $0.30 by your more intelligent wife and children (your words), got to do with my or your credibility in analysing CYP's commercial pathways and timelines?
CYP is fully enrolled on a phase III trial in Australia, conducted by UniSYd and funded by the Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant, results of which will be released in 1H 2026. $10 million Biomedical Translation Fund (BTF) grant to Cynata Therapeutics to support work on the large-scale manufacture of stem cells in 2022, etc, etc. Fortunately, people in positions of responsibility do not share your ignorance of how advanced CYP is in its regulatory and commercial pathways.
You really have shown yourself so utterly uninformed on CYP so many times, but insist on boring us all with unfounded and childlike FUD.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)